Literature DB >> 18406353

Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest.

Fang Sun1, Hanjiang Fu, Qin Liu, Yi Tie, Jie Zhu, Ruiyun Xing, Zhixian Sun, Xiaofei Zheng.   

Abstract

miRNAs regulate gene expression by inhibiting translation or by targeting messenger RNA (mRNA) for degradation in a post-transcriptional fashion. In the present study, we show that ectopic expression of miR-34a reduces both mRNA and protein levels of cyclin D1 (CCND1) and cyclin-dependent kinase 6 (CDK6). We also demonstrate that miR-34a targets the 3'-untranslated mRNA region of CCND1 as well as CDK6, which in turn interferes with phosphorylation of retinoblastoma. In addition, we show that overexpression of miR-34a induces a significant G1 cell-cycle arrest in the A549 cell line. Taken together, our data suggest that the effects of miR-34a on G1 cell cycle arrest are through the down-regulation of CCND1 and CDK6, which is associated with other targets of miR-34a either additively or synergistically.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18406353     DOI: 10.1016/j.febslet.2008.03.057

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  214 in total

Review 1.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

2.  Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth.

Authors:  Yong Zhao; Mei-Juan Tu; Yi-Feng Yu; Wei-Peng Wang; Qiu-Xia Chen; Jing-Xin Qiu; Ai-Xi Yu; Ai-Ming Yu
Journal:  Biochem Pharmacol       Date:  2015-10-27       Impact factor: 5.858

Review 3.  Strategies to Modulate MicroRNA Functions for the Treatment of Cancer or Organ Injury.

Authors:  Tae Jin Lee; Xiaoyi Yuan; Keith Kerr; Ji Young Yoo; Dong H Kim; Balveen Kaur; Holger K Eltzschig
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

Review 4.  Involvement of microRNAs in lung cancer biology and therapy.

Authors:  Xi Liu; Lorenzo F Sempere; Yongli Guo; Murray Korc; Sakari Kauppinen; Sarah J Freemantle; Ethan Dmitrovsky
Journal:  Transl Res       Date:  2011-02-04       Impact factor: 7.012

5.  A sensitive switch for visualizing natural gene silencing in single cells.

Authors:  Karmella A Haynes; Francesca Ceroni; Daniel Flicker; Andrew Younger; Pamela A Silver
Journal:  ACS Synth Biol       Date:  2012-03-16       Impact factor: 5.110

6.  Molecular and cellular pathways associated with chromosome 1p deletions during colon carcinogenesis.

Authors:  Claire M Payne; Cheray Crowley-Skillicorn; Carol Bernstein; Hana Holubec; Harris Bernstein
Journal:  Clin Exp Gastroenterol       Date:  2011-05-03

Review 7.  Targeting CSCs in tumor microenvironment: the potential role of ROS-associated miRNAs in tumor aggressiveness.

Authors:  Bin Bao; Asfar S Azmi; Yiwei Li; Aamir Ahmad; Shadan Ali; Sanjeev Banerjee; Dejuan Kong; Fazlul H Sarkar
Journal:  Curr Stem Cell Res Ther       Date:  2014-01       Impact factor: 3.828

8.  Hsa-miR-376c-3p targets Cyclin D1 and induces G1-cell cycle arrest in neuroblastoma cells.

Authors:  Swapnil Parashram Bhavsar; Cecilie Løkke; Trond Flægstad; Christer Einvik
Journal:  Oncol Lett       Date:  2018-09-11       Impact factor: 2.967

9.  MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes.

Authors:  Yunqing Li; Fadila Guessous; Ying Zhang; Charles Dipierro; Benjamin Kefas; Elizabeth Johnson; Lukasz Marcinkiewicz; Jinmai Jiang; Yanzhi Yang; Thomas D Schmittgen; Beatriz Lopes; David Schiff; Benjamin Purow; Roger Abounader
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

10.  Base-pair conformational switch modulates miR-34a targeting of Sirt1 mRNA.

Authors:  Ileana Guzzetti; Parisa Ebrahimi; Sarah Friebe Sandoz; Emilie Steiner; Lorenzo Baronti; Judith Schlagnitweit; Bastian Fromm; Luis Silva; Carolina Fontana; Alan A Chen; Katja Petzold
Journal:  Nature       Date:  2020-05-27       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.